Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Vancouver biotech company discovering antibodies for COVID-19 treatment

Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera

There may be another valuable shield in the fight against COVID-19, and the head of a Vancouver biotech firm says it could buy time as researchers race to develop a vaccine.

Carl Hansen, CEO of AbCellera Biologics Inc., said a drug built with antibodies could be used to protect vulnerable populations until a vaccine is more widely available.

The antibodies would give patients all the molecular material they need to fight the disease instead of depending on their bodies to develop their own as with a vaccine, giving them faster protection, he said.

“A prophylactic antibody could well be more effective than a vaccine,” he said.

On Sunday, Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera to support its work in discovering those antibodies using a high-tech platform.

The funding also supports the company’s plans to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

In partnership with pharmaceutical giant Eli Lilly, AbCellera is among a handful of companies on track for clinical trials this summer.

“There are many groups trying to rapidly develop vaccines for COVID-19 and vaccines are a very important part of the global response,” Hansen said.

“What we’re doing is different. What we’re doing is searching through an immune response that was generated from an actual infection and recovery in a patient and then finding that one antibody out of the literally millions that is best suited to stop the virus and that can be manufactured,” he said.

In 2012, Hansen said AbCellera recognized it could combine technologies from artificial intelligence, genomics, microfluidics and immunology to quickly search through natural immune systems to find antibodies that fight infection.

Two years ago, AbCellera began working with the Defense Advanced Research Projects Agency in the United States as part of a program to “radically accelerate” pandemic response, Hansen said. The company was working on simulations using its antibody-identifying technology when the COVID-19 pandemic struck.

“We quickly pivoted our efforts,” Hansen said.

Using blood samples from one of the first recovered COVID-19 patients in the United States on Feb. 25, AbCellera began screening millions of cells.

It narrowed down 500 unique human antibodies against the virus to a set of 24 that showed high promise of being therapeutic, he said.

“More recently we have further refined that set to a single antibody that is now being manufactured with the objective of having a first in-human trial start in July,” Hansen said.

What typically takes up to five years has been accelerated to less than four months, he said.

Vaccines and antibody-based prevention drugs work differently. With a vaccine, you inject a patient with a weakened virus or part of a virus to stimulate the immune system’s natural production of antibodies. With a prophylactic antibody, you insert the antibodies into the patient, Hansen said.

There are benefits and drawbacks. On one hand, prophylactics create more immediate protection because there’s no waiting period for the body to create its own antibodies. It’s also more broadly effective, because not all patients’ immune systems may be up to the task of producing their own antibodies.

On the other hand, a substantial number of antibodies must be administered to the patient in order to protect them.

“What that means is that the ability to manufacture hundreds of millions or even a billion doses of a vaccine is something well within the realm of possibility today. Making that many doses of antibodies is not,” he said.

That would mean giving the antibody to select groups of people at risk, such as health workers or the elderly, Hansen said.

The World Health Organization recommends that pharmacological treatment for COVID-19 should not be used outside of clinical trials.

On April 27, British Columbia’s COVID-19 therapeutics committee issued the same warning.

“There are no proven therapies for the prevention or treatment of COVID-19. All agents have the possibility of associated harm, and pharmaceutical supplies province-wide and nationally for many of the possible agents are severely limited,” it said.

For Hansen, research and development during the pandemic has not been business as usual.

“It’s not a race against our competitors nearly as much as it’s a race against the virus,” he said.

“What matters most is we get a therapy out there that works for patients and do so as quickly as possible.”

Amy Smart, The Canadian Press

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Mission woman wins $50,000 on a scratch ticket

Colleen Monds was speechless after realizing she won on a Casino Royale ticket

Employee at Shoppers Drug Mart in Mission tests positive for COVID-19

One of five BC locations to have positive tests last week for the Loblaws chain

UPDATE: Police seek driver in hit-and-run crash that injured pedestrian

Woman, 59, is in hospital in critical, but stable, condition

Police seek assistance locating missing Hope teen, last seen near Agassiz

RCMP say Jada Charlie-Carlson was last seen Monday in the 61000 block of Lougheed Highway

Green Party announces candidate for Maple Ridge-Mission

Trenholm running for first time in a closely contested riding

B.C. counts 125 new COVID-19 cases, up to 1,284 active

No new deaths or health care facility outbreaks

Health Canada green-lights rapid COVID-19 test

Health Canada approved the BCube test from Hyris Ltd. in the United Kingdom Sept. 23

6 puppies rescued in mass seizure on Princeton farm die from illness: BC SPCA

Of the 97 distressed horses, cats and dogs seized, most of the puppies suffered from parvo

Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

U.S. boater fined $1,000 for violation of Quarantine Act

49-year-old man entered Canada to visit girlfriend in Surrey

More sex abuse charges laid against B.C. man who went by ‘Doctor Ray Gaglardi’

Investigators now focussing efforts on alleged victims within the Glad Tidings Church community

B.C. VOTES 2020: Businesses now owe $6 billion in deferred tax payments

COVID-19 relief from remittance to province ends with September

Long-term care study credits fewer COVID deaths in B.C. than Ont. to funding, policy

The study was published Wednesday in the Canadian Medical Association Journal

UPDATE: NDP asks Elections BC to investigate Liberal voter fraud allegations in Surrey-Fleetwood

Liberal MLA candidate for Surrey-Fleetwood Garry Thind issued a written statement Wednesday afternoon

Most Read